BioNTech is revolutionizing vaccine technology using mRNA platforms designed to activate or modulate the immune system from different angles, each providing a distinct strategy to address cancer or prevent infectious disease. A robust mRNA innovation ecosystem that brings together industry, researchers, clinical investigators, and government can serve as a basis to build capabilities and expertise for the efficient and productive translation of mRNA research. 

In Australia, mRNA Victoria is responsible for identifying key capabilities, gaps and opportunities to lead the Victorian Government’s engagement, investment and partnerships in mRNA and RNA industry in Victoria. 

This panel discussion on “Accelerating the clinical translation of local mRNA breakthroughs and technologies into vaccines and therapeutics” will highlight the partnership between BioNTech and mRNA Victoria and the construction of a GMP mRNA manufacturing facility for a cancer-focused, clinical trials program in Australia.